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LETTERS TO THE EDITOR
Estrogen Receptor (ER)
and Epidermal Growth
Factor Receptor (EGFR)
as Targets for Dual
Lung Cancer Therapy:
Not Just a Case?
To the Editor:
A 57-year-old woman never smoker
with metastatic lung adenocarcinoma
was treated with cisplatin and vinorel-
bine but progression was observed in the
lung, bone, and skin.
The patient had severe bone pain
and multiple ulcerative bleeding skin le-
sions (Figure 1). Skin biopsywas performed
and compared with previous lung cancer
biopsies. Histologic examination confirmed
to be skin metastasis of lung adenocarci-
noma. The sample was thyroid transcription
factor-1, carcinoembryonic antigen, cytoker-
atin (CK), epidermal growth factor receptor
(EGFR), and estrogen receptor (ER) posi-
tive, whereas CK20, progesterone receptor
and Epidermal growth factor receptor 2
were negative.
Considering her never smoking
status, adenocarcinoma histopatology,
female gender and EGFR expression,
the second line treatment with gefitinib
was started in October 2005. After a few
weeks of treatment with gefitinib and
zoledronic acid partial recovery from
bone pain and initial healing of the mul-
tiple ulcerative subcutaneous lesions
was observed; the computed tomogra-
phy and the bone scans performed after
3 and 6 months of treatment with ge-
fitinib revealed disease stabilization but
no further clinical improvement of bone
pain and skin lesions at that time was
observed. No skin rash or remarkable
gastrointestinal toxicity was observed,
except for mild diarrhea (grade 1 ac-
cording National Cancer Institute toxic-
ity criteria) for few days after the begin-
ning of the therapy. Considering the
persistence of clinically relevant skin
lesions and the positive expression of
the ER in histologic samples, treatment
with aromatase inhibitor (letrozole) was
added to gefitinib in June 2006. This de-
cision was supported by data in vivo and
in vitro suggesting that association of ty-
rosine kinase inhibitor and hormonal ther-
apy can lead to significant suppression of
tumor cell growth.1–3 After 3 weeks of
therapy with gefitinib and letrozole
complete recovery from bone pain was
obtained and after 3 months complete
remission of cutaneous lesions was ob-
served (Figure 2).
Since June 2006, no clinical and
radiologic disease progression has been
detected. Currently treatment with ge-
fitinib and letrozole is well tolerated and
no toxicity from these two drugs has
been registered so far.
There is increasing evidence of sex
difference in the lung cancer risk and de-
velopment. Women are more susceptible
than men to the carcinogenic effects of
cigarette smoke taking into account base-
line exposure, body weight, height, and
body mass index. Female patients are also
2.5 times more likely to suffer from ade-
nocarcinoma which constitutes about one
third of primary lung cancer cases among
males and about three fourth of those
among females. Serum estrogen levels are
often higher in female lung cancer patients
compared with female without lung can-
cer suggesting that estrogens may be in-
volved in its etiology.1 In fact, they are
involved in differentiation of normal lung
epithelium and growth of non-small cell
lung cancers (NSCLCs), especially adeno-
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FIGURE 1. Shows one of the multiple ulcerative bleeding skin leasions at the time
of initial systemic progression.
FIGURE 2. Shows the complete remission of one of the skin lesions observed after
3 months of combination therapy.
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carcinomas both in vivo and in vitro.2
Lung cancer cells express both  and 
ER; the former, which seems to occur
more often in the lung of women than men
is localized in the cytoplasm, the latter in
the nucleus. Interesting data, regarding the
intense crosstalk between ERs and growth
factor such as EGF, are emerging.3–5
Direct binding of the ligand-ER
complex with steroid receptor coactivators
and estrogen receptor elements in DNA
leads to change in gene transcription that
regulate growth, differentiation, apoptosis,
and angiogenesis. Alternative pathways
may be activated by estrogen without di-
rect ER binding to DNA or by kinases
associated to epidermal growth factor re-
ceptor in the absence of estrogens. Many
rapid effects of estrogens may be also due
to activation of extranuclear signaling
pathways that are mediated by cell-surface
forms of ERs.
The interaction between ER and
EGFR/HER2 is demonstrated in NSCLC
cell lines as the treatment with estradiol
resulted in down-regulation of EGFR,
whereas treatment with the antiestrogen
fulvestrant increased the EGFR expres-
sion. In fact the combination of fulves-
trant and gefitinib in NSCLC may in-
hibit cell proliferation, induce apoptosis
and affect downstream signaling path-
ways. Moreover, ER  expression is
decreased in response to EGF and in-
creased in response to gefitinib.5
The recent evidence of crosstalk
between the EGFR and ER pathways,
along with the striking efficacy of ty-
rosine kinase inhibitors in women with
lung cancer and the emerging role of
estrogens in lung tumorigenesis, pro-
vides rationale to examine drugs that
target these two pathways for lung can-
cer treatment in selected patients.
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Use of Fluoroscopy
During Endobronchial
Ultrasonography for
Transbronchial Lung
Biopsies of Peripheral
Lung Lesions
To the Editor:
Fluoroscopic guidance in the per-
formance of transbronchial biopsies is
known to increase diagnostic yield by
allowing biopsies to accurately target
the area of interest.1 Diagnostic yields
have increased further with the introduc-
tion of Endobronchial Ultrasound using
Guide Sheath (EBUS-GS), with initial
reports utilizing fluoroscopic guidance
during the procedure.2 Recent reports
have suggested Endobronchial Ultra-
sound (EBUS) may be performed with-
out fluoroscopy.3 However, the authors
of this study noted a lower yield in
lesions in the right lower lobe, and at-
tributed this to movement of the probe
as a result of deep respiration. Dooms et
al.4 recently described the use of EBUS
bronchoscopy in bronchoscopically oc-
cult pulmonary lesions and noted that
for potentially fluoroscopically visible le-
sions (2 cm) no size difference was
noted between successfully diagnosed le-
sions and undiagnosed ones, suggesting
that further increasing accurate localiza-
tion of lesions using fluoroscopy may
have resulted in a further improved yield.
Our experience is that fluoroscopy is a
valuable tool in the performance of
EBUS-GS bronchoscopy as it is able to
confirm immediately before each biopsy
that specimens are taken from the area of
interest.
In support of this, we report a
60-year-old man, current smoker who
presented for bronchoscopy for investi-
gation of an incidental 2.6 cm right mid-
dle lobe nodule on computed tomogra-
phy chest (see Figure 1). Normal
endobronchial examination was fol-
lowed by EBUS-GS examination that
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FIGURE 1. CT chest demonstrating right middle lobe mass with dual “bronchus
sign” (arrow).
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